GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Short-Term Debt

Biomarin Pharmaceutical (FRA:BM8) Short-Term Debt : €0 Mil (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Short-Term Debt?

Biomarin Pharmaceutical's Short-Term Debt for the quarter that ended in Dec. 2024 was €0 Mil.

Biomarin Pharmaceutical's quarterly Short-Term Debt declined from Jun. 2024 (€460 Mil) to Sep. 2024 (€0 Mil) but then stayed the same from Sep. 2024 (€0 Mil) to Dec. 2024 (€0 Mil).

Biomarin Pharmaceutical's annual Short-Term Debt increased from Dec. 2022 (€0 Mil) to Dec. 2023 (€453 Mil) but then declined from Dec. 2023 (€453 Mil) to Dec. 2024 (€0 Mil).


Biomarin Pharmaceutical Short-Term Debt Historical Data

The historical data trend for Biomarin Pharmaceutical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Short-Term Debt Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 452.89 -

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 452.89 454.81 459.70 - -

Biomarin Pharmaceutical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Biomarin Pharmaceutical Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines